AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 66 min read$SKIN

SkinHealth Systems Inc. (SKIN): Results of Operations and Financial Condition

SkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SkinHealth Systems Reports Second Quarter 2026 Financial Results Long Beach, Calif., August 6, 2026 – SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the second

Original reporting
SEC EDGAR 8-K
Published Aug 6, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$SKIN
Neutral
medium confidence
Mentioned
$SKIN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SKINNeutralMed
01

Why it matters

Traders can update expectations using the revised Q3 and FY 2026 net sales and adjusted EBITDA ranges, and assess whether margin gains offset ongoing sales pressure.

02

Market read

The guidance ranges and the mix of sales decline versus margin/EBITDA improvement are the actionable elements for near-term positioning in SKIN.

03

What to watch

The filing attributes gross margin improvement to prior-year cost effects and notes distributor transitions in Australia/New Zealand and China, which may affect comparability and future sell-through.

Relevance 7/10Novelty 7/10Timing: after-hours filing today, guidance update for Q3 and FY 2026

Background

This is an SEC 8-K (Item 2.02) with Q2 2026 financial results and revised 2026 guidance for SkinHealth Systems, maker of Hydrafacial.

Company-level read

Ticker impact

$SKINNeutralMedium confidence
Context

SkinHealth Systems reported Q2 2026 results and revised 2026 guidance, including Q3 net sales $65-$70M and adjusted EBITDA $5-$7M.

Expected impact

Likely choppy reaction: upside support from higher adjusted EBITDA and gross margin, offset by weaker delivery systems and lower net sales.

Evidence & confidence

The filing discloses both a sales decline and improved gross margin/adjusted EBITDA, plus explicit revised Q3 and FY 2026 ranges that traders can reprice immediately.

Market effects

Sector

Provides a read-through for consumer/beauty device and recurring consumables models, highlighting sensitivity to delivery systems demand.

Regional

Regional net sales show weakness across Americas, APAC, and EMEA, with distributor transitions noted for Australia/New Zealand and China.

Global

Limited broader market impact; primarily company-specific repricing around guidance and installed-base productivity.

Counterpoint

What could challenge this read

The adjusted EBITDA outperformance may be partly cost-driven and could fade if delivery systems placements remain weak.

Key entities

  • company
    SkinHealth Systems Inc.

    NASDAQ-listed company reporting Q2 2026 results and revised 2026 guidance.

  • product/brand
    Hydrafacial

    Flagship brand referenced as central to the company’s franchise strategy.

  • executive
    Pedro Malha

    CEO quoted on sales pressure, margin improvement, and strategic priorities.

Read at source← All news

Related articles

SEP 15
$SKINLowAI 8/10

SkinHealth Unveils HydraScalp, Hydrafacial Data; Shows Skin And Scalp Benefits

SkinHealth Systems (SKIN) announced clinical data on HydraScalp and Hydrafacial treatments, showing improvements in scalp and skin health. Studies found significant benefits, including increased hydration and reduced dandruff for HydraScalp, and enhanced skin quality for Hydrafacial. The company will present findings at the 2026 Science of Skin Summit. SKIN's stock is currently at $0.70, up 0.04%.

rttnews.com2 min
JUL 7
$SKINMedAI 8/10

SkinHealth Systems Inc.: SkinStylus Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types

SkinHealth Systems (NASDAQ: SKIN) said the FDA cleared its SkinStylus SteriLock microneedling device to improve periorbital wrinkles in adults 22+ for all Fitzpatrick skin types. The clearance expands indications to include facial acne scars and abdominal hypertrophic scars. The company cited 2025 U.S. microneedling spend of about $330M (+33% YoY) and noted Hydrafacial pairing interest.

finanznachrichten.de4 min
SEP 15
$NVDAMedAI 8/10

Nvidia, Broadcom Just Helped Break a 90-Year Earnings Trend—Now Comes the Hard Part - State Street SPDR S

Nvidia (NVDA) and Broadcom (AVGO) reported strong Q2 earnings, with NVDA's EPS up 113.5% YoY and AVGO's up 96.4%. S&P 500 earnings grew 31%, exceeding expectations, driven by AI sector growth of 54%. This marks the first time in 90 years earnings exceeded the trend line. RIA Advisors notes two potential outcomes: sustained AI growth or normalization of profits.

benzinga.com3 min